医药魔方 / 最新资讯 / 正文

博瑞医药获得顶级资本青睐,完成5.5亿元融资

医药魔方 医药魔方 来源:医药魔方
2019-01-08
博瑞生物
原文

近日,博瑞生物医药(苏州)股份有限公司(以下简称“博瑞医药”)宣布完成5.5亿元Pre-IPO轮融资,本轮融资由红杉资本中国基金、弘晖资本共同领投,广发乾和参与投资。

 

博瑞医药是由“千人计划”特聘专家袁建栋博士创立的“国家级高新技术企业”,致力于开发和生产原创性新药和高难度仿制药,为临床未被满足的需求寻找解决方案。博瑞医药以强大的研发实力为发展基石,依靠全球化的注册能力和商业化能力,以及与国际接轨的cGMP生产质量体系,取得了快速发展,已成为涵盖研发、生产、销售全产业链的医药集团。博瑞医药组建了300人的研发团队,每年研发投入超过营业收入的25%;生产质量管理体系通过欧、美、日、韩认证的cGMP;在欧美市场首仿上市了恩替卡韦、卡泊芬净、阿尼芬净等产品;成功开发了艾日布林、曲贝替定、磺达肝癸钠等高端仿制药,在抗肿瘤、超级抗生素、静脉补铁等领域建立起具有全球竞争优势的产品线。包括国投、中金、华泰、基石等多家知名投资基金驻扎其中。

 

公司董事长袁建栋表示,本轮融资的资金主要用于两个方面:一方面是投入创新药物的开发以及临床。之前公司储备了一些“全球新”的原创candidate,由于依靠自身业务的利润滚动开发,项目推进较慢。增量资金将为快速推动这些创新药的进展起到积极作用。另一方面,本轮融资的部分资金将用于原料工厂的产能提升和注射剂工厂的建设,该注射剂工厂为全球市场生产复杂注射剂,是公司未来利润的主要来源。

    

红杉资本中国基金副总裁徐强表示,“‘一致性评价+集中采购’将促使医药行业格局加速洗牌。我们看重企业的核心价值以及技术壁垒所形成的竞争优势。博瑞生物专注于竞争者少、技术难度特别大的高端原料药和制剂领域,定位清晰;基于多手性药物平台、发酵半合成平台、非生物大分子平台以及靶向高分子偶联平台,开发储备了一批技术壁垒高的产品;同时构建了从高难度中间体、高端原料药到制剂的完整产业链,在未来的产业整合中具有较强的竞争优势。我们看好博瑞医药长期发展的潜力和持续动力,愿意支持这类优秀企业的长久稳健发展。”

 

弘晖资本合伙人何幸表示,“我们很高兴与红杉资本中国基金合作投资并服务博瑞医药。博瑞医药是研发驱动的高科技制药企业,其核心产品在全球市场上处于领先地位,管理团队经验丰富,尤其是在董事长袁建栋的带领下,充分发挥了核心技术能力和运营执行能力双轮驱动的竞争优势。”

 

关于红杉资本中国基金


红杉资本始终致力于帮助创业者成就基业常青的伟大公司,为成员企业带来丰富的全球资源和宝贵的历史经验。47 年来,红杉资本投资了众多创新企业和产业潮流的领导者。红杉资本中国基金作为「创业者背后的创业者」,专注于科技/传媒、医疗健康、消费品/服务、工业科技四个方向的投资机遇。十四年来,红杉资本中国基金投资了超过 500 家具有鲜明技术特征、创新商业模式、具备高成长性和高发展潜力的企业。

 

关于弘晖资本


弘晖资本是一家专注于医疗健康产业的投资基金,管理着美元和人民币双币种5只主基金。弘晖资本的投资专注于生物医药、医疗器械等。投资组合包括:迈瑞医疗(300760)、鱼跃医疗(002223)、药明康德(603259)、康龙化成(300759)、开拓药业、百洋医药、圣湘生物、科美诊断、马泷齿科、朝聚眼科等一批优质企业。


关于广发乾和


广发乾和投资有限公司是广发证券股份有限公司(股票代码:000776.SZ ,1776.HK)全资设立的另类投资子公司。广发乾和目前主要从事股权投资业务,具有行业领先的股权投资规模和能力,并致力于帮助优质客户通过资本运作成长为细分行业的领军者。


医药领域是广发乾和重点布局的行业方向之一,其投资了青岛百洋、康龙化成、卡威生物、越洋医药、阿康健康等一批优质企业。


机器翻译

Recently, Borui Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Borui Pharmaceutical") announced the completion of 5.500 million pre-IPO round of financing, this round of financing led by Sequoia Capital China Fund, Honghui Capital, Guangfa dry and participate in investment.

Borui Pharmaceutical is a "national high-tech enterprise" founded by Dr. Yuan Jiandong, a special expert of the "Thousand Talents Program". It is committed to the development and production of original new drugs and difficult generic drugs to find solutions for unmet clinical needs.With its strong R & D strength as the cornerstone of development, Borui Pharmaceutical has achieved rapid development by relying on its global registration and commercialization capabilities, as well as its cGMP production quality system in line with international standards, and has become a pharmaceutical group covering R & D, production, and sales of the entire industry chain.Borui Pharmaceutical has set up a research and development team of 300 people with R & D investment exceeding 25% of its operating income each year; the production quality management system has passed the certified cGMP in Europe, the United States, Japan, and South Korea; it has first listed entecavir, caspofungin, anidulafungin, and other products in the European and American markets; it has successfully developed high-end generic drugs such as eribulin, trabetidine, and fondaparinux, and has established a product line with global competitive advantages in the fields of anti-tumor, super antibiotics, and intravenous iron supplementation.Including SDIC, CICC, Huatai, the cornerstone of a number of well-known investment funds stationed.

Yuan Jiandong, chairman of the company, said that the funding for this round of financing is mainly used in two aspects: on the one hand, it is invested in the development of innovative drugs and clinical.The company has previously stocked up some "new global" originals, and the project has been slow to advance due to the rolling development of profits from its own business.Incremental funding will play a positive role in the rapid advancement of these innovative drugs.On the other hand, some of the funds for this round of financing will be used to increase the capacity of raw material factories and the construction of injection factories, which produce complex injections for the global market and are the main source of future profits for the company.Xu Qiang, vice president of Sequoia Capital China Fund, said: "'Consistency assessment + centralized procurement' will accelerate the reshuffle of the pharmaceutical industry.We value the core value of the enterprise and the competitive advantage of technical barriers.Borui Bio focuses on high-end raw material medicines and preparations with few competitors and particularly difficult technologies, and has a clear positioning. Based on multi-chiral drug platforms, fermentation semi-synthetic platforms, non-biological macromolecular platforms, and targeted polymer coupling platforms, it has developed and stocked a number of products with high technical barriers. At the same time, it has built a complete industrial chain from difficult intermediates, high-end raw material medicines to preparations, and has a strong competitive advantage in future industrial integration.We are optimistic about the potential and sustained momentum of Borui Pharmaceutical's long-term development and are willing to support the long-term and steady development of such outstanding enterprises."We are pleased to work with Sequoia Capital China Fund to invest and serve Borui Pharmaceuticals," said He Xing, partner of Honghui Capital.Borui Pharmaceutical is a high-tech pharmaceutical company driven by R & D. Its core products are in the leading position in the global market, and its management team has rich experience. Especially under the leadership of Chairman Yuan Jiandong, Borui Pharmaceutical has brought into full play the competitive advantage of two-wheel drive of core technology capabilities and operational execution capabilities."

About Sequoia Capital China Fund

Sequoia Capital has always been committed to helping entrepreneurs become evergreen companies, bringing rich global resources and valuable historical experience to member companies.For 47 years, Sequoia Capital has invested in a number of innovative companies and industry leaders.Sequoia Capital China Fund, as an entrepreneur behind entrepreneurs, focuses on investment opportunities in four directions: technology/media, healthcare, consumer goods/services, and industrial technology.In the past 14 years, Sequoia Capital China Fund has invested more than 500 companies with distinctive technical features, innovative business models, and high growth and development potential.

About Honghui Capital

Honghui Capital is an investment fund focused on the healthcare industry, which manages five main funds in both US dollar and RMB.Honghui Capital's investment focuses on biomedicine, medical devices, etc.The investment portfolio includes: Mindray Medical (300760), Yuyue Medical (002223), WuXi PharmaTech (603259), Kanglong Huacheng (300759), Pioneering Pharmaceuticals, Baiyang Pharmaceutical, Shengxiang Biological, Kemei Diagnostics, Ma Yi Dental, Chaoju Ophthalmology and other high-quality enterprises.

On GF & H

GF & E Investment Co., Ltd. is GF Securities Limited (stock code: 000776.SZ, 1776.HK) a wholly owned alternative investment subsidiary.Guang Fa Gan and currently mainly engaged in equity investment business, with industry-leading equity investment scale and capabilities, and committed to helping high-quality customers through capital operations to grow into leaders in the subdivision industry.

The medical field is one of the industry directions of Guangfa Gansu and its key layout. It has invested in Qingdao Baiyang, Kanglong Huacheng, Kawai Bio, Yueyang Pharmaceutical, and Akang Health.

扫码实时看更多精彩文章

版权及免责声明 本文由医药魔方原创,版权归医药魔方所有。未经许可,严禁任何媒体或个人以任何形式摘编、改写、复制、转载本文内容。对于恶意侵权行为,医药魔方保留采用法律手段追究的权利。媒体内容及商务合作请联系医药魔方工作人员(微信号:medicube)

魔方微信公众号